Follow WHO guidelines for COVID‐19 diagnosis
Consider NAFLD as a prognostic factor for severe COVID‐19
Screen patients for hepatitis B surface antigen
Consider HBV prophylaxis prior to use of anti‐IL‐6, other immunosuppressive therapy
Monitor liver function tests of patients with CLD
Be alert to possible drug hepatotoxicity
Decompensated CLD and ALT >5 times ULD contraindications for remdesivir therapy
Prioritize persons with CLD for clinical trials